Retour
5
Fourchette du Jour
7,17 €
7,17 €
Fourchette 52 Semaines
7,17 €
8,66 €
Volume
1
Moyenne 50J / 200J
7,17 €
/
7,40 €
Clôture Précédente
7,17 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (626 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 0,5 | 0,4 |
| P/B | 0,1 | 2,9 |
| ROE % | 16,0 | 3,7 |
| Net Margin % | 6,6 | 3,8 |
| Rev Growth 5Y % | 5,6 | 10,0 |
| D/E | 1,2 | 0,2 |
Points Clés
Revenue grew 5,58% annually over 5 years — modest growth
Earnings grew 16,28% over the past year
ROE of 15,99% — decent returns on equity
Generating 122,15M in free cash flow
P/E of 0,49 — trading at a low valuation
PEG of 0,52 suggests growth is underpriced
Croissance
Revenue Growth (5Y)
5,58%
Revenue (1Y)4,53%
Earnings (1Y)16,28%
FCF Growth (3Y)-68,68%
Qualité
Return on Equity
15,99%
ROIC8,52%
Net Margin6,62%
Op. Margin10,28%
Sécurité
Debt / Equity
1,19
Current Ratio1,15
Interest Coverage42,22
Valorisation
P/E Ratio
0,49
P/B Ratio0,08
EV/EBITDA4,40
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 4,53% | Revenue Growth (3Y) | 5,43% |
| Earnings Growth (1Y) | 16,28% | Earnings Growth (3Y) | 17,76% |
| Revenue Growth (5Y) | 5,58% | Earnings Growth (5Y) | 22,70% |
| Profitability | |||
| Revenue (TTM) | 26,34B | Net Income (TTM) | 1,74B |
| ROE | 15,99% | ROA | 5,96% |
| Gross Margin | 49,70% | Operating Margin | 10,28% |
| Net Margin | 6,62% | Free Cash Flow (TTM) | 122,15M |
| ROIC | 8,52% | FCF Growth (3Y) | -68,68% |
| Safety | |||
| Debt / Equity | 1,19 | Current Ratio | 1,15 |
| Interest Coverage | 42,22 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 0,49 | P/B Ratio | 0,08 |
| P/S Ratio | 0,03 | PEG Ratio | 0,52 |
| EV/EBITDA | 4,40 | Dividend Yield | 0,00% |
| Market Cap | 854,53M | Enterprise Value | 11,93B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 26,34B | 25,20B | 23,70B | 21,64B | 21,20B |
| Net Income | 1,74B | 1,50B | 1,26B | 1,01B | 769,00M |
| EPS (Diluted) | 12,70 | 10,88 | 9,40 | 7,20 | 5,40 |
| Gross Profit | 13,09B | 12,46B | 11,76B | 10,55B | 10,45B |
| Operating Income | 2,71B | 3,16B | 2,72B | 2,46B | 2,08B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 29,23B | 28,39B | 27,80B | 26,27B | 25,62B |
| Total Liabilities | 18,24B | 17,42B | 16,76B | 15,33B | 15,03B |
| Shareholders' Equity | 10,87B | 10,93B | 11,02B | 10,89B | 10,58B |
| Total Debt | 12,97B | 12,65B | 12,30B | 10,86B | 10,88B |
| Cash & Equivalents | 1,89B | 1,80B | 2,28B | 1,50B | 1,46B |
| Current Assets | 6,51B | 6,38B | 6,43B | 5,44B | 5,60B |
| Current Liabilities | 5,65B | 6,26B | 5,60B | 5,28B | 5,62B |
Scores de Stratégies
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#596 of 658
Activité Récente
Entré
Contrarian Investing (David Dreman)
Mar 24, 2026